NCT07129239 (HEIRLOOM) is a Phase 3 clinical trial of Maintenance in Wet Age-related Macular Degeneration (wAMD), sponsored by Clinique de Retine de l'est.

Who is sponsoring NCT07129239?

NCT07129239 is sponsored by Clinique de Retine de l'est.

What drugs are being tested in NCT07129239?

Interventions in NCT07129239: Maintenance.

What condition does NCT07129239 study?

NCT07129239 studies Wet Age-related Macular Degeneration (wAMD).

Is NCT07129239 still recruiting?

NCT07129239 is currently not yet recruiting. Last updated 11 August 2025.

Last reviewed 2025-08-11 · How we verify

NCT07129239: HEIRLOOM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)

Not yet recruiting Phase 3 Last updated 11 August 2025

What this trial tests

Phase 3 trial testing Maintenance in Wet Age-related Macular Degeneration (wAMD) in 180 participants. Not yet recruiting.

Timeline

20 August 2025

Primary endpoint
1 February 2027

1 February 2027

Quick facts

Lead sponsor	Clinique de Retine de l'est
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	180
Start date	20 August 2025
Primary completion	1 February 2027
Estimated completion	1 February 2027
Sites	1 location across Canada

Drugs / interventions tested

Maintenance — full drug profile →

Conditions studied

Wet Age-related Macular Degeneration (wAMD) — all drugs for Wet Age-related Macular Degeneration (wAMD) →

Sponsor

Clinique de Retine de l'est

Who can join

18 and older, any sex, with Wet Age-related Macular Degeneration (wAMD). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Central Retinal Thickness (CRT)
Time frame: 6 and 12 month
The primary endpoint will derived from Optical Coherence Tomography (OCT), in µm and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).

Sponsor's own description

The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg). EYLEA® HD is approved by Health Canada has been tested in large clinical trials involving thousands of patients around the world and has been shown effective in the treatment of wAMD. The treatment regimen used in these trials involved 3 initial monthly injections of EYLEA® HD followed by an extension of the treatment interval on the 4th visit. This was necessary since all patients in this study did not previously have treatment injections for wAMD. Currently there is not enough information on the best treatment regimen to use for patients that are switched to EYLEA® HD from EYLEA®. Health Canada currently recommends that EYLEA® HD is administered every month for the first 3 doses, followed by a treatment every 8 to 16 weeks. A total of 180 patients \>18 years of age will participate in this study, which will be conducted at the Clinique de Retine de l'Est in Montreal, Quebec, Canada.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Maintenance

Trials testing the same drug.

NCT06646380 — Physical Fitness, Sleep Quality, Dynamic Balance and Exercise in Aged People · NA · completed
NCT05623449 — Teleconsultations Hypnosis Sessions for Patients with Peripheral Chronic Neuropathic Pain · NA · completed
NCT03668379 — An Adaptive Intervention for Depression Among Latinos Living With HIV · NA · completed
NCT04628520 — Surgical Protocol for Prevention of Mucositis · NA · unknown
NCT02067143 — MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate · Phase 2 · completed

Other recruiting trials for Wet Age-related Macular Degeneration (wAMD)

Currently open trials in the same condition.

NCT06718816 — Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD · recruiting
NCT06707753 — Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07129239 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clinique de Retine de l'est
Last refreshed: 11 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07129239.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing